Association between growth differentiation factor-15 and chronic heart failure in coronary atherosclerosis patients

Genetics and Molecular Research

Volumn 14, Issue 1, 2015, Pages 2225-2233

  Zhu, Z D ^a   Sun, T ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Association analysis; Chronic heart failure; Growth differentiation factor 15; N terminal pro brain natriuretic peptide; ROC curve

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GROWTH DIFFERENTIATION FACTOR 15; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE MARKER; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN CONFORMATION; BLOOD; CHRONIC DISEASE; CORONARY ARTERY DISEASE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; RECEIVER OPERATING CHARACTERISTIC; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; CHRONIC DISEASE; CORONARY ARTERY DISEASE; ECHOCARDIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; ROC CURVE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84925964849     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2015.March.27.8     Document Type: Article

References (30)

1. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, et al. (1997). MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc. Natl. Acad. Sci. U. S. A. 94: 11514-11519.
2. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, et al. (2003). ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography-summary article: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J. Am. Coll. Cardiol. 42: 954-970.
3. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, et al. (2011). Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann. Med. 43: 60-68.
4. Goldsmith SR and Gheorghiade M (2005). Vasopressin antagonism in heart failure. J. Am. Coll. Cardiol. 46: 1785-1791.
5. Hunt SA (2005). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. Cardiol. 46: e1-e82.
6. Kempf T and Wollert KC (2009). Growth Iqbal N, Alim KS, Aramin H, Iqbal F, et al. (2013). Novel biomarkers for heart failure. Expert Rev. Cardiovasc. Ther. 11: 1155-1169.
7. differentiation factor-15: a new biomarker in cardiovascular disease. Herz 34: 594-599.
8. Kempf T, Eden M, Strelau J, Naguib M, et al. (2006). The transforming growth factor-beta superfamily member growthdifferentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ. Res.98: 351-360.
9. Kempf T, Horn-Wichmann R, Brabant G, Peter T, et al. (2007a). Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin. Chem. 53: 284-291.
10. Kempf T, von Haehling S, Peter T, Allhoff T, et al. (2007b). Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J. Am. Clin. Cardiol. 50: 1054-1060.
11. Kempf T, Sinning JM, Quint A, Bickel C, et al. (2009). Growth-differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease: results from the AtheroGene study. Circ. Cardiovasc. Genet. 2: 286-292.
12. Kempf T, Zarbock A, Widera C, Butz S, et al. (2011). GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat. Med. 17: 581-588.
13. Khan SQ, Ng K, Dhillon O, Kelly D, et al. (2009). Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur. Heart J. 30: 1057-1065.
14. Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, et al. (2010). Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin. Res. Cardiol.99: 323-328.
15. Lok DJ, Klip IT, Lok SI, Bruggink-André de la Porte PW, et al. (2013). Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure. Am. J. Cardiol. 112: 831-837.
16. Lok SI, Winkens B, Goldschmeding R, van Geffen AJ, et al. (2012). Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur. J. Heart Fail. 14: 1249-1256.
17. Meeran K, O’Shea D, Upton PD, Small CJ, et al. (1997). Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study. J. Clin. Endocrinol. Metab. 82: 95-100.
18. Meier-Ewert HK, Ridker PM, Rifai N, Regan MM, et al. (2004). Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J. Am. Coll. Cardiol. 43: 678-683.
19. Morgenthaler NG, Struck J, Alonso C and Bergmann A (2006). Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin. Chem. 52: 112-119.
20. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, et al. (2007). IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117: 1538-1549.
21. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, et al. (2010). Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur. J. Heart Fail. 12: 826-832.
22. Szinnai G, Morgenthaler NG, Berneis K, Struck J, et al. (2007). Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J. Clin. Endocrinol. Metab. 92: 3973-3978.
23. Tan M, Wang Y, Guan K and Sun Y (2000). PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. Proc. Natl. Acad. Sci. USA 97: 109-114.
24. Tsutamoto T, Hisanaga T, Wada A, Maeda K, et al. (1998). Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J. Am. Coll. Cardio. 31: 391-398.
25. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, et al. (2006). Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J. Am. Clin. Cardiol. 48: 1217-1224.
26. von Haehling S, Filippatos GS, Papassotiriou J, Cicoira M, et al. (2010). Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur. J. Heart Fail. 12: 484-491.
27. Wollert KC and Kempf T (2012). GDF-15 in heart failure: providing insight into end-organ dysfunction and its recovery? Eur. J. Heart Fail. 14: 1191-1193.
28. Wollert KC, Kempf T, Lagerqvist B, Lindahl B, et al. (2007a). Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation 116: 1540-1548.
29. Wollert KC, Kempf T, Peter T, Olofsson S, et al. (2007b). Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 115: 962-971.
30. Xu J, Kimball TR, Lorenz JN, Brown DA, et al. (2006). GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ. Res.98: 342-350.